Anadys Pharmaceuticals, Inc. (ANDS) Reports Q2 EPS Loss of $0.14
Tweet
Share
E-mailGet Alerts ANDS Hot Sheet
Price: $3.70 --0%
Financial Fact:
Research and development: 7.99M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Financial Fact:
Research and development: 7.99M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) reported Q2 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- SentinelOne, Inc. (S) Tops Q2 EPS by 1c; offers guidance
- Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
